A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.
|Articles|June 18, 2006
- Applied Clinical Trials-06-19-2006
- Volume 0
- Issue 0
TAKE Solutions, ACI, and OnSphere Merge to Create TAKE Solutions, Global Life Sciences and the OneClinical Brand
OneClinical Provides a Full Spectrum of Software Products and Services for the Regulated Life Sciences Industry.
Advertisement
Princeton, NJ-June 12, 2006-Today TAKE Solutions, Inc. announced the formation of the OneClinical™ brand of life sciences offerings as part of its merger with Applied Clinical Intelligence (Philadelphia, PA) and OnSphere Corporation (Raleigh, NC). OneClinical combines a full spectrum of proven data and document management software products and services for clinical trials, drug and device development lifecycles.
"The merger of TAKE Solutions, ACI, and OnSphere enhances our ability to help our clients improve efficiencies in drug and medical device development and product safety. We can now offer our clients global scalability as well as a robust suite of regulatory-compliant process efficiency software" said Dr. Jonathan Seltzer, President, ACI & Chief Medical Officer, TAKE Solutions Global Life Sciences.
Articles in this issue
over 20 years ago
BBK Healthcare, Inc. Evolves to Become BBK Worldwideover 20 years ago
Datafarm Announces the Release of Web-Based eCTD ViewerAdvertisement
Related to this article
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Why clinical development’s next AI bottleneck is not the model, but the system around it.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines
The pilot pairs drug sponsors with qualified research institutions to compress the path from drug identification to first-in-human study through rolling submission review and earlier coordination of institutional review board and site activation activities.
A Syneos Health-announced study from Tufts Center for the Study of Drug Development finds no single sourcing model consistently outperforms others, pointing instead to vendor coordination, governance, and fit-for-purpose design as the real performance drivers.
Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities
2
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
3
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
4
What "Patient Voice" Actually Requires: Beyond the Buzzword
5